Condition (MeSH)
Foot Deformities, Acquired
ClinicalTrials.gov lists 325 trials for Foot Deformities, Acquired or a narrower condition beneath it. Pacira Pharmaceuticals, Inc has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 of the 325 trials are tagged with Foot Deformities, Acquired itself; the rest are tagged with a narrower condition beneath it.
When did Foot Deformities, Acquired trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 36
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 26 |
| 2025 | 32 |
| 2024 | 36 |
| 2023 | 27 |
| 2022 | 29 |
| 2021 | 26 |
| 2020 | 17 |
| 2019 | 15 |
| 2018 | 20 |
| 2017 | 9 |
Showing 10 of 25 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 33 trials starting in 2026 and about 33 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 32 months from start to primary completion across 22 trials still running at the 2026-10-09 snapshot; registered median of 10 months across 202 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Foot Deformities, Acquired trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 1 |
| Phase 2 | 13 |
| Phase 2/3 | 2 |
| Phase 3 | 17 |
| Phase 4 | 10 |
| Not applicable | 185 |
| Observational | 94 |
How many Foot Deformities, Acquired trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 20 |
| Recruiting | 30 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 11 |
| Completed | 180 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Foot Deformities, Acquired trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pacira Pharmaceuticals, Inc | 5 |
| Baudax Bio | 4 |
| Heron Therapeutics | 4 |
| Cali Pharmaceuticals LLC | 3 |
Which drugs are being tested for Foot Deformities, Acquired? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| +/- Bupivacaine HCl | 10 |
| Oxycodone | 2 |
| Meloxicam | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Exercise | 4 |
| type A botulinum toxin | 4 |
| Conventional Therapy | 3 |
| Intranasal Dexmedetomidine | 2 |
| Ropivacaine 2 % | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Foot Deformities, Acquired trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Atrial septal defect | 2 | 1 |
| Deep vein thrombosis | 2 | 2 |
| Deep vein thrombosis postoperative | 2 | 1 |
| Impaired healing | 2 | 1 |
| Allergic reaction | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Foot Deformities, Acquired? (54)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Patient Outcomes Following Extra-Osseous Talo-Tarsal Stabilization for Foot Hyperpronation. | The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons | 2022 | Yes |
| Outcome After Modified Grice-Green Procedure (SAMBB) for Arthritic Acquired Adult Flatfoot. | Foot & ankle international | 2020 | Yes |
| Distribution of the Highest Plantar Pressure Regions in Patients with Diabetes and Its Association with Peripheral Neuropathy, Gender, Age, and BMI: One Centre Study. | Journal of diabetes research | 2019 | Yes |
| Short- to Mid-Term Outcomes Following the Use of an Arthroereisis Implant as an Adjunct for Correction of Flexible, Acquired Flatfoot Deformity in Adults. | Foot & ankle specialist | 2019 | Yes |
| Surgical offloading procedures for diabetic foot ulcers compared to best non-surgical treatment: a study protocol for a randomized controlled trial. | Journal of foot and ankle research | 2018 | Yes |
Showing 5 of 54 publications.
Sub-conditions in MeSH (4)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.